Eli Lilly, a global pharmaceutical company, has announced the launch of Copellor®(Ixekizumab) in India. This drug has been approved by The Drug Controller General of India (DCGI) for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy, as well as treatment of adult patients with active psoriatic arthritis.
Copellor®(Ixekizumab) is a humanized IgG4 monoclonal antibody that specifically targets IL-17A, a protein that plays a role in triggering and maintaining inflammation in psoriasis. Vineet Gupta, Managing Director of Eli Lilly and Company – India & India Subcontinent, said, “The availability of a new treatment like Copellor®(Ixekizumab) will now empower healthcare providers with another option for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy, as well as treatment of adult patients with active psoriatic arthritis, a huge unmet need in the country.”
Psoriasis has a major impact on the quality of life of patients and is comparable to serious diseases such as cancer and heart failure. Copellor®(Ixekizumab) is a prescription medicine that should only be used on the advice of a dermatologist or rheumatologist and under medical supervision. It is available in one strength of 80 mg/ml in a single-dose prefilled autoinjector.
the launch of Copellor®(Ixekizumab) in India is a significant move by Eli Lilly to address the unmet needs of patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. This drug has the potential to improve the quality of life for patients suffering from these diseases, and the availability of this treatment option is a step forward in the field of dermatology in India.